CHMP recommends marketing authorisation for Kizfizo
The Committee for Medicinal Products for Human Use adopted a positive opinion on 15 October 2026, recommending a marketing authorisation for Kizfizo, a 40 mg/ml oral suspension of temozolomide, for newly diagnosed glioblastoma multiforme in adults and for recurrent or progressing malignant glioma in adults and children from the age of one year. The applicant is Orphelia Pharma and the product is designated an orphan medicine.
Primary source
EMA medicine page (CHMP opinion), October 16, 2026
Kizfizo (temozolomide): EMA CHMP opinion
Read the source: Kizfizo (temozolomide): EMA CHMP opinion ema.europa.eu
Machine-summarized from the source above; not independently reported. How we use automation